Table 3. Risk assessments on various factors for therapeutic failure.
| Factors | OR* (95% CI*) | P values |
|---|---|---|
| Age | ||
| <45 | 1 | |
| ≥45 | 0.722(0.448–1.164) | 0.180 |
| Gender | ||
| Female | 1 | |
| Male | 1.520(0.874–2.645) | 0.138 |
| Size of tumor | ||
| ≤1 cm | 1 | |
| >1 cm | 1.779(1.051–3.009) | 0.032 |
| Capsular invasion | ||
| No | 1 | |
| Yes | 1.506(0.935–2.424) | 0.092 |
| Pathological tumor stage | ||
| T1 | 1 | |
| T2 | 1.529(0.784–2.982) | 0.213 |
| T3 | 2.025(1.208–3.394) | 0.007 |
| T4 | 11.800(1.498–92.978) | 0.019 |
| LN* metastasis | ||
| N0 | 1 | |
| N1a | 1.406(0.850–2.324) | 0.185 |
| N1b | 4.783(2.245–10.190) | <0.001 |
| TNM* stage | ||
| Stage I | 1 | |
| Stage II | 0.945(0.366–2.440) | 0.907 |
| Stage III | 0.875(0.514–1.489) | 0.623 |
| Stage IV | 2.005(0.949–4.232) | 0.068 |
| ATA risks* | ||
| Low risk | 1 | |
| Intermediate risk | 1.852(1.145–2.996) | 0.012 |
| High risk | 20.263(2.263–155.837) | 0.004 |
| Time interval between surgery and 131I therapy | ||
| <3 months | 1 | |
| ≥3 months | 1.077(0.575–2.020) | 0.816 |
| Pre-ablation Tg* (ng/ml) | ||
| <3.525 | 1 | |
| ≥3.525 | 9.649(5.651–16.473) | <0.001 |
| Pre-ablation TSH* (uIU/ml) | ||
| <99.700 | 1 | |
| ≥99.700 | 0.547(0.345–0.867) | 0.002 |
*OR = odds ratio, CI = confidence interval, LN = lymph node, TNM stage = American Joint Committee on Cancer tumor-node-metastasis staging system, ATA risks = American Thyroid Association risks, Tg = thyroglobulin, TSH = thyroid stimulating hormone.